---
title: "Silexion Therapeutics Corp (SLXN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SLXN.US.md"
symbol: "SLXN.US"
name: "Silexion Therapeutics Corp"
industry: "Biotechnology"
datetime: "2026-06-10T02:44:37.112Z"
locales:
  - [en](https://longbridge.com/en/quote/SLXN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SLXN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SLXN.US.md)
---

# Silexion Therapeutics Corp (SLXN.US)

## Company Overview

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [ilexion.com](https://ilexion.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.14 | 82 | - | - | - |
| PB | 6.00 | 355 | 1.45 | 0.99 | 0.78 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-28T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 142.57 |
| Highest Target | 750.00 |
| Lowest Target | 750.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SLXN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SLXN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SLXN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SLXN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**